Date: 2016-02-09
Type of information: Collaboration agreement
Compound: IMMray™ PanCan-d (blood based test for early detection of pancreatic cancer)
Company: Immunovia (Sweden) Mount Sinai Health System (USA - NY)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: collaboration
Action mechanism: diagnostic test/biomarker signature. The test is a microchip with a panel of clinically relevant antibodies which is called a biomarker signature. The signature binds with extremely high specificity and sensitivity in a specific pattern the proteins that are present in the blood sample and are associated with the disease. The test can give a clear answer about the presence or absence of the disease in early stages. The technology comes from Professor Carl Borrebaeck and his research team at Create Health Cancer Center.
Disease: pancreatic cancer
Details: * On February 9th, 2016, Immunovia announced that Mount Sinai Health System will be one of the first sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting second half of 2016. Under the agreement, Mount Sinai will contribute together with the other sites to the development of the prospective study clinical protocol, obtaining the required approvals to recruit study subjects and following them up over a period of three years, delivering the blood samples for analysis and finally disseminating the results to clinicians and patients. In addition to the collaboration with Mount Sinai Health System, Immunovia announced a partnership with Knight Cancer Institute at Oregon Health and Sciences University, and the University of Liverpool.
Financial terms:
Latest news:
